The Motor Function Measure (MFM), a reliable tool assessing motor function and its progression in most neuromuscular diseases, is widely used in France in many teams. It can be used regardless of the severity of the motor impairment or the ambulatory status of the patient, allowing its use throughout the whole follow-up period of the patient, even in case of the loss of walking. Two versions of the MFM exist, one composed of 32 items originally validated for patients from 6 years old (MFM-32) and a shorter version composed of 20 items originally validated for patients between 2 and 6 years old (MFM-20). In order to prove the possible use of MFM-32 as early as the age of 2 years to validly and reliably monitor the evolution of the motor function of children treated with Nusinersen, we propose in this project to study the sensitivity to treatment-induced change of MFM-32 and the validity of the scale in this population.
Study Type
OBSERVATIONAL
Enrollment
33
Service de neuropédiatrie et neurochirurgie de l'enfant Centre de Référence des Maladies Neuromusculaires AOC CHU d'Angers
Angers, France
Centre de Référence des maladies neuromusculaires Centre Hospitalier Régional Universitaire de Brest
Brest, France
L'Escale, Service central de rééducation pédiatrique Hospices Civils de Lyon Hôpital Mere Enfant
Bron, France
Service de génétique médicale Pôle de Pédiatrie CHU Estaing
Clermont-Ferrand, France
Service de Neurologie et réanimation pédiatriques
Garches, France
Apf Esean
Nantes, France
Institut I-Motion - Centre de recherche pédiatrique en pathologies neuromusculaires
Paris, France
Service de pédiatrie CHU de Saint-Etienne
Saint-Priest-en-Jarez, France
Service de Neuropédiatrie CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Unité de Neurologie Pédiatrique Centre de Référence Maladies NeuroMusculaires Hôpital des Enfants CHU Toulouse
Toulouse, France
MFM-32 responsiveness
Responsiveness of MFM-32 in comparison to PGIC. The responsiveness sensitivity to change indexes considered will be the effect size (ES) amplitude and the Standardized Response Mean (SRM)
Time frame: 1 Year after the first MFM-32 assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.